BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation

BioInvent International AB ( (SE:BINV) ) has provided an announcement.

BioInvent International AB announced that the European Medicines Agency’s Committee for Orphan Medicinal Products has given a positive opinion for Orphan Drug Designation to its investigational product BI-1808 for treating Cutaneous T-cell Lymphoma (CTCL). This designation is expected to promote the development of drugs for rare diseases, offering incentives like protocol assistance and market exclusivity. BI-1808 has shown promising clinical activity with a 100% disease control rate in a Phase 2a trial, and it is well-tolerated with mild to moderate adverse events. The European Commission is anticipated to grant the designation within 30 days, which underscores BioInvent’s commitment to advancing novel immunotherapies for underserved hematologic malignancies.

The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK34.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.

More about BioInvent International AB

BioInvent International AB is a clinical-stage biotech company specializing in the discovery and development of novel, first-in-class immuno-modulatory antibodies for cancer therapy. The company is engaged in ongoing clinical programs in Phase 1/2 trials for treating hematological cancer and solid tumors. BioInvent’s proprietary F.I.R.S.T technology platform aids in identifying targets and antibodies, facilitating the development of promising drug candidates and offering licensing and partnering opportunities. The company also generates revenue through research collaborations, license agreements, and antibody production for third parties.

YTD Price Performance: -21.69%

Average Trading Volume: 107,570

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK1.98B

For an in-depth examination of BINV stock, go to TipRanks’ Overview page.